MX2019009724A - Nueva estrategia de inmunoterapia dirigida al vegfr-2. - Google Patents
Nueva estrategia de inmunoterapia dirigida al vegfr-2.Info
- Publication number
- MX2019009724A MX2019009724A MX2019009724A MX2019009724A MX2019009724A MX 2019009724 A MX2019009724 A MX 2019009724A MX 2019009724 A MX2019009724 A MX 2019009724A MX 2019009724 A MX2019009724 A MX 2019009724A MX 2019009724 A MX2019009724 A MX 2019009724A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- protein receptor
- vegf
- copy
- dna molecule
- Prior art date
Links
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 title 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 7
- 201000011510 cancer Diseases 0.000 abstract 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 6
- 108020004414 DNA Proteins 0.000 abstract 3
- 102000053602 DNA Human genes 0.000 abstract 3
- 241000607142 Salmonella Species 0.000 abstract 3
- 230000002238 attenuated effect Effects 0.000 abstract 3
- 238000002619 cancer immunotherapy Methods 0.000 abstract 3
- 206010009944 Colon cancer Diseases 0.000 abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 2
- 201000005202 lung cancer Diseases 0.000 abstract 2
- 208000020816 lung neoplasm Diseases 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 208000002458 carcinoid tumor Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4225—Growth factors
- A61K40/423—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001135—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pregnancy & Childbirth (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17156718 | 2017-02-17 | ||
| PCT/EP2018/053918 WO2018149982A1 (en) | 2017-02-17 | 2018-02-16 | Novel vegfr-2 targeting immunotherapy approach |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019009724A true MX2019009724A (es) | 2019-10-07 |
Family
ID=58094260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019009724A MX2019009724A (es) | 2017-02-17 | 2018-02-16 | Nueva estrategia de inmunoterapia dirigida al vegfr-2. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10980868B2 (OSRAM) |
| EP (1) | EP3583200A1 (OSRAM) |
| JP (2) | JP7712060B2 (OSRAM) |
| KR (2) | KR20240170928A (OSRAM) |
| CN (1) | CN110291187A (OSRAM) |
| AU (1) | AU2018222777B9 (OSRAM) |
| BR (1) | BR112019016925A2 (OSRAM) |
| CA (1) | CA3050833A1 (OSRAM) |
| IL (1) | IL268186A (OSRAM) |
| MX (1) | MX2019009724A (OSRAM) |
| RU (1) | RU2019125436A (OSRAM) |
| SG (1) | SG11201907391SA (OSRAM) |
| WO (1) | WO2018149982A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107995868B (zh) * | 2015-06-18 | 2021-07-13 | 万科斯蒙股份有限公司 | 用于联合治疗的vegfr-2靶向dna疫苗 |
| EP3846844A1 (en) * | 2018-09-05 | 2021-07-14 | Vaximm AG | Neoantigen targeting dna vaccine for combination therapy |
| US20230121528A1 (en) * | 2020-01-13 | 2023-04-20 | Vaximm Ag | Salmonella-based dna vaccines in combination with an antibiotic |
| CN113527509B (zh) * | 2020-04-17 | 2023-09-26 | 深圳华大生命科学研究院 | 含有重组蛋白和保护蛋白的复合物在治疗肺鳞癌中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO337687B1 (no) | 2011-07-08 | 2016-06-06 | Norsk Elektro Optikk As | Hyperspektralt kamera og metode for å ta opp hyperspektrale data |
| LT2794849T (lt) | 2011-12-22 | 2017-12-11 | Vaximm Ag | Didelio produktyvumo susilpnintų salmonella padermių gamybos būdas |
| PL2869836T3 (pl) * | 2012-07-05 | 2020-03-31 | Vaximm Ag | Szczepionka DNA do zastosowania u pacjentów z rakiem trzustki |
| WO2014173542A1 (en) * | 2013-04-25 | 2014-10-30 | Vaximm Ag | Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1 |
| KR20160130979A (ko) * | 2013-12-18 | 2016-11-15 | 백심 게엠베하 | 암 면역요법을 위한 신규한 msln 표적화 dna 백신 |
| WO2015142875A1 (en) * | 2014-03-17 | 2015-09-24 | The Trustees Of The University Of Pennsylvania | Compositions and methods using modified salmonella |
| CN107995868B (zh) | 2015-06-18 | 2021-07-13 | 万科斯蒙股份有限公司 | 用于联合治疗的vegfr-2靶向dna疫苗 |
| US10821163B2 (en) | 2016-07-13 | 2020-11-03 | Vaximm Ag | Process for the production of a DNA vaccine for cancer immunotherapy |
-
2018
- 2018-02-16 WO PCT/EP2018/053918 patent/WO2018149982A1/en not_active Ceased
- 2018-02-16 KR KR1020247035606A patent/KR20240170928A/ko active Pending
- 2018-02-16 AU AU2018222777A patent/AU2018222777B9/en active Active
- 2018-02-16 KR KR1020197026398A patent/KR20190117603A/ko not_active Ceased
- 2018-02-16 MX MX2019009724A patent/MX2019009724A/es unknown
- 2018-02-16 SG SG11201907391SA patent/SG11201907391SA/en unknown
- 2018-02-16 RU RU2019125436A patent/RU2019125436A/ru not_active Application Discontinuation
- 2018-02-16 CN CN201880012318.8A patent/CN110291187A/zh active Pending
- 2018-02-16 JP JP2019544614A patent/JP7712060B2/ja active Active
- 2018-02-16 CA CA3050833A patent/CA3050833A1/en active Pending
- 2018-02-16 US US16/486,425 patent/US10980868B2/en active Active
- 2018-02-16 EP EP18704568.7A patent/EP3583200A1/en active Pending
- 2018-02-16 BR BR112019016925-3A patent/BR112019016925A2/pt not_active Application Discontinuation
-
2019
- 2019-07-21 IL IL268186A patent/IL268186A/en unknown
-
2023
- 2023-08-18 JP JP2023133276A patent/JP2023160838A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US10980868B2 (en) | 2021-04-20 |
| KR20190117603A (ko) | 2019-10-16 |
| EP3583200A1 (en) | 2019-12-25 |
| JP2023160838A (ja) | 2023-11-02 |
| JP2020507332A (ja) | 2020-03-12 |
| US20200038496A1 (en) | 2020-02-06 |
| WO2018149982A1 (en) | 2018-08-23 |
| AU2018222777B9 (en) | 2024-02-22 |
| JP7712060B2 (ja) | 2025-07-23 |
| AU2018222777A1 (en) | 2019-08-08 |
| IL268186A (en) | 2019-09-26 |
| KR20240170928A (ko) | 2024-12-05 |
| RU2019125436A (ru) | 2021-03-17 |
| AU2018222777B2 (en) | 2024-02-01 |
| BR112019016925A2 (pt) | 2020-05-26 |
| CA3050833A1 (en) | 2018-08-23 |
| SG11201907391SA (en) | 2019-09-27 |
| CN110291187A (zh) | 2019-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guiu et al. | Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions? | |
| CY1124006T1 (el) | Συζευγμενα αντισωματα κατα toy ly75 για τη θεραπεια του καρκινου | |
| CY1123355T1 (el) | Αντισωματα εναντι cd73 και χρησεις εξ αυτων | |
| MX2019008503A (es) | Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos. | |
| AR097584A1 (es) | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano | |
| MX2019009724A (es) | Nueva estrategia de inmunoterapia dirigida al vegfr-2. | |
| BR112019001922A2 (pt) | receptores de célula t e imunoterapia usando os mesmos | |
| UY36289A (es) | ANTICUERPOS MONOCLONALES QUE ENLAZAN INMUNOESPECIFICAMENTE A CD123 y COMPOSICIONES QUE LOS CONTIENEN | |
| HK1250918A1 (zh) | 用於胶质母细胞瘤的egfr导向的car疗法 | |
| CO2017010502A2 (es) | Receptores del antígeno quimérico dirigidos al antígeno de maduración de células b | |
| MX2022014630A (es) | Composicion para tratar el cancer, destruir las celulas cancerosas metastasicas y evitar la metastasis del cancer. | |
| MX2019011656A (es) | Formatos mejorados de receptor de union a antigeno. | |
| MX364922B (es) | Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer. | |
| MX380358B (es) | Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer. | |
| WO2012054084A3 (en) | Antibodies | |
| EP2582727A4 (en) | ANTIBODIES TO ENDOPLASMINE AND ITS USE | |
| DOP2014000199A (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina | |
| MX352373B (es) | Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno. | |
| CY1119351T1 (el) | Αντισωματα σε adp-ριβοζυλ κυκλαση 2 | |
| MX2019011026A (es) | Nueva vacuna de adn dirigida a pd-l1 para inmunoterapia de cancer. | |
| EA201690806A1 (ru) | Антитела | |
| PH12016502297A1 (en) | Ang2 antibodies | |
| Kocáková et al. | Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours. | |
| AR097996A1 (es) | Anticuerpos | |
| Goto et al. | Supplementary Material for: Oligophrenin-1 Is Associated with Cell Adhesion and Migration in Prostate Cancer |